Back to Browse Journals » Clinical Ophthalmology » Volume 7

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

Authors Thomas M, Mousa SS, Mousa SA

Published Date March 2013 Volume 2013:7 Pages 495—501

DOI http://dx.doi.org/10.2147/OPTH.S29974

Received 15 November 2012, Accepted 5 February 2013, Published 8 March 2013

Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1

1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA

Abstract: Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United States. Many treatments, such as laser therapy and photodynamic therapies, have been used but their efficacy is limited. Emerging anti-vascular endothelial growth factor (VEGF) therapies are now considered the standard of care. Anti-VEGF agents inhibit angiogenesis in the eye by suppressing abnormal blood vessel growth, leading to vision improvement. Ranibizumab and bevacizumab are two examples of anti-VEGF drugs that have been approved; both showed promise based on the visual acuity scale. Aflibercept, another new therapy known to trap VEGF and inhibit multiple growth factors, is promising not only because it can be taken bimonthly based on year 1 of the VIEW trials, but it can also be extended, as demonstrated in year 2 of the VIEW trials. Based on a cost–effect analysis, aflibercept is comparable to other leading therapies. This is a review of relevant clinical trials that have proven the non-inferiority and safety of aflibercept compared to the standard of care and its unique role in the current management of wet AMD.

Keywords: aflibercept, VEGF, anti-VEGF, pegatanib, bevacizumab, ranibizumab, VIEW trials

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Current primary open-angle glaucoma treatments and future directions

Beidoe G, Mousa SA

Clinical Ophthalmology 2012, 6:1699-1707

Published Date: 23 October 2012

Biosensors: the new wave in cancer diagnosis

Brian Bohunicky, Shaker A Mousa

Nanotechnology, Science and Applications 2011, 4:1-10

Published Date: 30 December 2010

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

Sarah Rofaiel, Esther N Muo, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2010, 3:129-143

Published Date: 17 September 2010

Prevention strategies for antimicrobial resistance: a systematic review of the literature

Whitney P Caron, Shaker A Mousa

Infection and Drug Resistance 2010, 3:25-33

Published Date: 21 May 2010

Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine

Peter Avery, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:79-91

Published Date: 13 September 2009

The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent

Hector Clarke, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:93-99

Published Date: 10 September 2009

Pharmacogenomics in osteoporosis: Steps toward personalized medicine

Robert Greene, Shaymaa S Mousa, Mohamed Ardawi, et al

Pharmacogenomics and Personalized Medicine 2009, 2:69-78

Published Date: 10 September 2009

Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine

Christopher Barone, Shaymaa S Mousa, Shaker A Mousa

Pharmacogenomics and Personalized Medicine 2009, 2:59-67

Published Date: 8 September 2009

Readers of this article also read:

Retinal vascular tortuosity in obstructive sleep apnea

Mohsenin A, Mohsenin V, Adelman RA

Clinical Ophthalmology 2013, 7:787-792

Published Date: 26 April 2013

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients

Yamamoto A, Okada AA, Sugitani A, Kunita D, Rii T, Yokota R

Clinical Ophthalmology 2013, 7:757-763

Published Date: 19 April 2013

Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal

Suzuki T, Hayakawa K, Nakagawa Y, Onouchi H, Ogata M, Kawai K

Clinical Ophthalmology 2013, 7:549-553

Published Date: 19 April 2013

Corneal sensitivity after topical bromfenac sodium eye-drop instillation

Yanai K, Huang J, Kadonosono K, Uchio E

Clinical Ophthalmology 2013, 7:741-744

Published Date: 17 April 2013

Association of age and macular pigment optical density using dual-wavelength autofluorescence imaging

Lima VC, Rosen RB, Prata TS, Dorairaj S, Spielberg L, Maia M, Sallum JM

Clinical Ophthalmology 2013, 7:685-690

Published Date: 4 April 2013

Can intramuscular corticosteroid injection cause nonarteritic anterior ischemic optic neuropathy?

Bakbak B, Ozturk BT, Gedik S, Koktekir BE, Gonul S

Clinical Ophthalmology 2013, 7:633-635

Published Date: 26 March 2013

Emerging roles for antiangiogenesis factors in management of ocular disease

Saeed MU, Gkaragkani E, Ali K

Clinical Ophthalmology 2013, 7:533-543

Published Date: 13 March 2013

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

Vottonen P, Kaarniranta K, Pääkkönen A, Tarkka IM

Clinical Ophthalmology 2013, 7:437-442

Published Date: 27 February 2013